Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...
The data engineer started as a casual reader of the Jeffrey Epstein files. Then he became obsessed, and built the most ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results